Beta Thalassemia Plasma

Beta Thalassemia Plasma for Hemoglobinopathy and Iron Overload Research

Our Beta Thalassemia Plasma is sourced from IRB-consented donors clinically diagnosed with beta thalassemia, an inherited hemoglobin disorder caused by reduced or absent beta-globin chain synthesis. Each sample is processed and frozen within 24 hours of collection to preserve circulating iron-regulatory proteins, erythropoietic markers, and inflammatory mediators relevant to disease pathophysiology.

Beta Thalassemia Biology and Why Plasma

• Beta thalassemia results from mutations in the HBB gene that reduce or eliminate beta-globin production, causing an excess of unpaired alpha-globin chains that precipitate in erythroid precursors and drive ineffective erythropoiesis and hemolysis.
• Chronic anemia and ineffective erythropoiesis suppress hepcidin, the master regulator of iron homeostasis, leading to progressive iron overload even in the absence of transfusion; transfusion-dependent patients face additional iron burden from repeated red cell transfusions.
• Plasma is the preferred matrix for iron-regulatory biomarkers including hepcidin, soluble transferrin receptor, ferritin, and erythroferrone, as well as markers of oxidative stress from iron-catalyzed reactions.
• Disease severity spans a clinical spectrum from transfusion-dependent thalassemia (TDT) to non-transfusion-dependent thalassemia (NTDT), each with distinct iron-overload kinetics and complication profiles.
• Newer therapeutics targeting ineffective erythropoiesis (luspatercept) and gene therapies (betibeglogene autotemcel) have created demand for biomarkers that track erythropoietic and iron-status response to treatment.

Donor Stratification Available

• Genotype and mutation type (beta-zero versus beta-plus)
• Clinical severity: transfusion-dependent (TDT) versus non-transfusion-dependent (NTDT)
• Transfusion history and chelation therapy status
• Splenectomy status
• Iron overload markers where available (ferritin, liver iron concentration)
• Age band and sex assigned at birth
• Matched healthy controls available

Product Features

• Collected from clinically confirmed beta thalassemia donors
• Processed and frozen within 24 hours of collection
• Research Use Only (RUO)
• IRB-approved protocols with documented consent
• Standard and custom aliquot volumes available

De-identified Donor Data

• Beta thalassemia diagnosis confirmation and genotype where documented
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Transfusion, chelation, and treatment history where documented
• Additional thalassemia-specific metadata available on request

Applications

• Iron-regulatory biomarker profiling (hepcidin, ferritin, soluble transferrin receptor, erythroferrone)
• Erythropoietic marker analysis and ineffective erythropoiesis studies
• Pharmacodynamic monitoring for erythroid maturation agents and gene therapies
• Oxidative stress and iron-catalyzed damage marker studies
• Biomarker development for transfusion and chelation management

Other Beta Thalassemia Specimen Types

• Beta Thalassemia Serum

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Beta thalassemia plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare donor availability across conditions, visit our human plasma page.